MDGL Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales 6 hours ago Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported fourth-quarter 2025 results showing continued commercial uptake of its lead product Rezdiffra (resmetirom), with… Madrigal Pharmaceuticals, Inc (MDGL) Q1 2022 Earnings Call 4 years ago Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) Q1 2022 Earnings Conference